

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Orion Health Group Limited
Date this disclosure made:	1-Jun-17
Date of last disclosure:	19-Jan-17
Director or senior manager giving disclosure	
Full name(s):	Ian Richard McCrae
Name of listed issuer:	Orion Health Group Limited (OHE)
Name of related body corporate (if applicable):	Not applicable
Position held in listed issuer:	Director and Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding	
specified derivatives)	
Class of affected quoted financial products:	Ordinary shares in OHE (Ordinary Shares)
	Beneficial interest in Shares held by Orion Health Corporate Trustee
Nature of the affected relevant interest(s):	Limited as trustee for the Orion Health Long Term Incentive Scheme
	(Scheme)
For that relevant interest-	
Number held in class before acquisition or disposal:	147,250 Shares
Number held in class after acquisition or disposal:	91,000 Shares
Current registered holder(s):	
Registered holder(s) once transfers are registered:	
Summary of acquisition or disposal of specified derivatives	
relevant interest (if applicable)	
Type of affected derivative:	Not applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of	
underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically	
settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the	
consideration payable under the derivative or the value of the derivative	
is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the	
nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	1-Jun-17
	Redemption and cancellation of unvested Shares under the Scheme
Nature of transaction:	as the applicable performance hurdles were not met
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received	
for the acquisition or disposal. If the consideration was not in cash and	
cannot be readily by converted into a cash value, describe the	
consideration:	Not applicable
Number of financial products to which the transaction related:	. 1

f the issuer has a financial products trading policy that prohibits	
lirectors or senior managers from trading during any period without	
vritten clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed	
period:	No
Whether prior written clearance was provided to allow the acquisition or	
lisposal to proceed during the closed period:	Not applicable
Date of the prior written clearance (if any):	
action of the prior financial action (in any)	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	Shares
Nature of relevant interest:	(a), (b) Beneficial interest in Shares (c) Legal interest in Shares
For that relevant interest,-	
Number held in class:	(a) 80,860,057 (b) 165,773 (c) 178,280
Number field in class.	(a) McCrae Limited (b) Ian Richard McCrae, Rosemary McCrae and
Current registered holder(s):	Gregory Thomas Walker (c) Ian Richard McCrae
For a derivative relevant interest,-	
Fype of derivative:	Not applicable
Oetails of derivative,-	Trot approacts
The notional value of the derivative (if any) or the notional amount of	
	¥
anderlying financial products (if any): A statement as to whether the derivative is cash settled or physically	
	2
settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the	
consideration payable under the derivative or the value of the derivative	
s affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
f the director or senior manager is not a party to the derivative, the	
nature of the relevant interest in the derivative:	
Certification	
certify that, to the best of my knowledge and belief, the information	
contained in this disclosure is correct and that I am duly authorised to	
make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	1
Dr .	4/
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	1-Jun-17
Name and title of authorised person:	Helen Dymond, Legal Counsel
Notes	
lee this form to disclose all the acquisitions, and disposals by a director	

or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within-

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.